BIND, Pfizer ally to develop highly targeted Accurins therapies

04/4/2013 | Genetic Engineering & Biotechnology News

Pfizer and BIND Therapeutics agreed to collaborate in the development and marketing of Accurins, a new class of highly targeted and programmable treatments, using the latter's Medicinal Nanoengineering platform. The partners will jointly conduct preclinical research, and Pfizer has the right to develop and market the Accurins it chooses. BIND could get $50 million in upfront and development milestone fees from Pfizer. BIND is also eligible to receive around $160 million in regulatory and sales milestone fees for each Accurin that is commercialized, plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA